Why Is Buffett Buying Verisign?
Warren Buffett has spent 2024 stockpiling cash, even going so…
Sell
43
ALT Quote, Financials, Valuation and Earnings
Last price:
$7.35
Seasonality move
:
3.74%
Day range:
$7.48 - $8.03
52-week range:
$5.28 - $14.84
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
10,004.58x
P/B ratio:
4.09x
Volume:
1.9M
Avg. volume:
3.4M
1-year change:
-32.42%
Market cap:
$545.5M
Revenue:
$426K
EPS (TTM):
-$1.57
Analysts' Opinion
-
Consensus RatingAltimmune has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $22.86, Altimmune has an estimated upside of 198.01% from its current price of $7.67.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $12.00 representing 100% downside risk from its current price of $7.67.
Fair Value
-
According to the consensus of 5 analysts, Altimmune has 198.01% upside to fair value with a price target of $22.86 per share.
ALT vs. S&P 500
-
Over the past 5 trading days, Altimmune has underperformed the S&P 500 by -6.86% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Altimmune does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Altimmune revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Altimmune reported revenues of $5K.
Earnings Growth
-
Altimmune has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Altimmune reported earnings per share of -$0.32.
Enterprise value:
406.1M
EV / Invested capital:
3.05x
Price / LTM sales:
10,004.58x
EV / EBIT:
--
EV / Revenue:
7,810.49x
PEG ratio (5yr expected):
-2.51x
EV / Free cash flow:
-5.20x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-58.37%
Net Income Margin (TTM):
-199076.92%
Return On Equity:
-64.43%
Return On Invested Capital:
-64.43%
Operating Margin:
-495340%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $3.3M | $279K | $52K | $362K | $5K | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$85.3M | -$85.4M | -$99.5M | -$22.5M | -$24.8M | |
| EBITDA | -$86.7M | -$77.8M | -$103.2M | -$20.5M | -$22.8M | |
| Diluted EPS | -$1.91 | -$1.54 | -$1.57 | -$0.39 | -$0.32 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $218.1M | $218.3M | $211M | $153M | $145.8M | |
| Total Assets | $233M | $236.9M | $225.3M | $166.6M | $147.9M | |
| Current Liabilities | $6.3M | $19.1M | $15.7M | $11.9M | $8.6M | |
| Total Liabilities | $33.3M | $27.6M | $20.2M | $16.2M | $14.5M | |
| Total Equity | $199.7M | $209.3M | $205M | $150.4M | $133.4M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$67.2M | -$76.6M | -$78.1M | -$20.5M | -$27.1M | |
| Cash From Investing | -$49.5M | $22.7M | -$50M | $4.4M | $1.2M | |
| Cash From Financing | $69.4M | $13.3M | $72.7M | $588K | $266K | |
| Free Cash Flow | -$67.5M | -$76.7M | -$78.1M | -$20.5M | -$27.1M | |
ALT
Sector
Market Cap
$545.5M
$45.9M
Price % of 52-Week High
51.69%
46.95%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
-32.42%
-32.15%
Beta (5-Year)
0.155
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$7.97
200-day SMA
Buy
Level
$7.39
Bollinger Bands (100)
Buy
Level
6.31 - 8.31
Chaikin Money Flow
Sell
Level
-283.2M
20-day SMA
Sell
Level
$8.60
Relative Strength Index (RSI14)
Sell
Level
43.68
ADX Line
Sell
Level
12.74
Williams %R
Buy
Level
-88.5299
50-day SMA
Sell
Level
$7.97
MACD (12, 26)
Sell
Level
-0.10
25-day Aroon Oscillator
Sell
Level
-60
On Balance Volume
Neutral
Level
583.2M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (25.4843)
Sell
CA Score
(Annual)
Level (-0.4982)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (8.1438)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (1)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company’s pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
Stock Forecast FAQ
In the current month, ALT has received 4 Buy ratings 1 Hold ratings, and 0 Sell ratings. The ALT average analyst price target in the past 3 months is $22.86.
-
Where Will Altimmune Stock Be In 1 Year?
According to analysts, the consensus estimate is that Altimmune share price will rise to $22.86 per share over the next 12 months.
-
What Do Analysts Say About Altimmune?
Analysts are divided on their view about Altimmune share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Altimmune is a Sell and believe this share price will drop from its current level to $12.00.
-
What Is Altimmune's Price Target?
The price target for Altimmune over the next 1-year time period is forecast to be $22.86 according to 5 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is ALT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Altimmune is a Buy. 4 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ALT?
You can purchase shares of Altimmune via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Altimmune shares.
-
What Is The Altimmune Share Price Today?
Altimmune was last trading at $7.35 per share. This represents the most recent stock quote for Altimmune. Yesterday, Altimmune closed at $7.67 per share.
-
How To Buy Altimmune Stock Online?
In order to purchase Altimmune stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Microsoft an Undervalued Growth Stock to Buy?
Tech giant Microsoft (NASDAQ:MSFT) has been one of the biggest…
Will Tesla Go Up or Down in 2025?
The last few months have been exciting for Tesla and…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 115x
Buy
54
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
50
LMND alert for Dec 30
Lemonade [LMND] is down 2.82% over the past day.
Buy
63
SMLR alert for Dec 30
Semler Scientific [SMLR] is down 11.17% over the past day.
Sell
39
DOGZ alert for Dec 30
Dogness (International) [DOGZ] is up 3.61% over the past day.
